Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07659795 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
A Phase 2 study, sponsored by Verastem.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT07659795 is a Phase 2 study that is actively recruiting participants, run by Verastem. The registered enrollment target is 150 participants.
The verdict
NCT07659795, a Phase 2 study, is actively recruiting participants, sponsored by Verastem.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Interventions
- DRUG cetuximab
- DRUG panitumumab
- DRUG VS-7375
- DRUG Cetuximab + mFOLFOX6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07659795
The ClinicalTrials.gov registry entry for NCT07659795 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cetuximab is the first listed.
NCT07659795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07659795 about?
NCT07659795 is a clinical study titled "A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer". This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
What is the current status of trial NCT07659795?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2026-07. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07659795?
The interventions under investigation include: cetuximab (DRUG), panitumumab (DRUG), VS-7375 (DRUG), Cetuximab + mFOLFOX6 (DRUG).
Who is sponsoring clinical trial NCT07659795?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.